Clinical trials: Vasoplegia Syndrome
Vasoplegic Syndrome, Sirs Due to Noninfectious Process Without Organ Dysfunction
RaGuS Trial by Postoperative Patients
Vasoplegic syndrome is characterized clinically by reduced systemic vascular resistance and normal or increased cardiac output. It is principally observed in cardiovascular and orthopedic interventions and is characterized by a…
- Conditions
- Vasoplegic Syndrome, Sirs Due to Noninfectious Process Without Organ Dysfunction, Orthostatic Hypotension
- Trial name
- RaGuS (NCT04440085)
- Testing
- Midodrine Hydrochloride
- Volunteers
- 50 people
- Sponsor
- Bürgerspital Solothurn
Vasoplegic Syndrome
Vitamin B12a Vasoplegic Syndrome
The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.
- Trial name
- NCT03735316
- Testing
- Hydroxocobalamin, Cardiopulmonary Bypass
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Sepsis, Vasoplegia
Occult Vasoplegia in Normotensive Sepsis: Early Prediction With Diastolic Index and Lactate
The goal of this observational study is to learn if the Diastolic Shock Index (DSI) and initial lactate can predict occult vasoplegia in adults with normotensive sepsis.
- Conditions
- Sepsis, Vasoplegia, Septic Shock
- Trial name
- DIAL-SEPSIS (NCT07658014)
- Where
- Mexico
- Volunteers
- 526 people
- Sponsor
- Hospital H+ Queretaro
Vasoplegic Syndrome
Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.
After cardiac surgery, vasoplegic syndrome is a hemodynamic state characterized by profound hypotension associated with a decrease in systemic vascular resistance.
- Trial name
- SNEAD (NCT02479529)
- Testing
- Norepinephrine
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Septic Shock, Vasopressor Resistance
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock
Septic shock is one of the most frequent reasons for admission to intensive care units and remains associated with a high mortality rate of approximatively 40% at 28 days.
- Trial name
- ADRESS (NCT07569536)
- Testing
- Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care
- Where
- 18 sites in France
- Volunteers
- 360 people
- Sponsor
- Hospices Civils de Lyon
Liver Diseases, Reperfusion Injury
Effect Inhaled Nitric Oxide in Adult Liver Transplant
Liver transplantation remains the only cure for patients with end-stage liver disease. Despite continuous advances in medical care, ischemia-reperfusion injury (IRI) (tissue damage that occurs when blood supply is restored to an…
- Conditions
- Liver Diseases, Reperfusion Injury, Vasoplegia
- Trial name
- NCT07125443
- Testing
- Prospective iNO Administration ("After" Group), No Intervention Retrospective "Before" Group
- Volunteers
- 260 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Shock, Septic, Critically Ill
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
Sepsis has been characterised as a dysregulated host response to infection. Adjunctive therapies targeting the inflammatory cascade are being increasingly explored, although to date, have failed to demonstrate consistent benefit…
- Conditions
- Shock, Septic, Critically Ill, Vasoplegic Syndrome, Sepsis
- Trial name
- VITAMINS (NCT03333278)
- Testing
- Vitamin C, Thiamine, Hydrocortisone,
- Where
- 8 sites in Australia, Brazil and 1 more
- Volunteers
- 216 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre